Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience.

Yan, Ningning; Guo, Sanxing; Huang, Siyuan; Zhang, Huixian; Li, Xingya

Yan, Ningning; Guo, Sanxing; Huang, Siyuan; Zhang, Huixian; Li, Xingya.

Afiliação

Yan N; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Guo S; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Huang S; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhang H; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Li X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Front Oncol ; 14: 1412472, 2024.

Article em En | MEDLINE | ID: mdl-38887239